Adult urologyOA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate
References (22)
Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate
J Urol
(1991)- et al.
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
J Urol
(1993) - et al.
Aid to accurate clinical staging—histopathologic grading in prostatic cancer
J Urol
(1982) - et al.
Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression
J Urol
(1993) - et al.
Expression of the c-erbB2 (HER-2/neu) oncoprotein in human prostatic carcinoma
J Urol
(1993) - et al.
p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate
J Urol
(1992) - et al.
Overexpression of HER-2/NEU may be an indicator of poor prognosis in prostate cancer
J Urol
(1993) - et al.
Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer
- et al.
Fatty acid synthesis: a potential selective target for antineoplastic therapy
- et al.
Expression of the progestin-induced fatty acid synthetase in benign mastopathies and breast cancer as measured by RNA in situ hybridization
J Natl Cancer Inst
(1990)
Haptoglobin-related protein (Hpr) epitopes in breast cancer as a predictor of recurrence of the disease
N Engl J Med
Cited by (200)
Endoplasmic reticulum stress and lipids in health and diseases
2023, Progress in Lipid ResearchCitation Excerpt :Higher levels of fatty acid synthase during pancreatic cancer progression positively correlated with poor survival of patients and spontaneous pancreatic in cancer mouse models [200]. Some patients exhibited resistance to treatment assumably due to the alterations in lipid metabolism [201–203]. Inhibiting de novo lipid synthesis in cancer cells partially alleviates drug resistance by activating the PERK-CHOP axis.
Cancer metabolism
2020, An Innovative Approach to Understanding and Treating Cancer: Targeting pH: From Etiopathogenesis to New Therapeutic AvenuesLipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention
2020, Advanced Drug Delivery ReviewsCitation Excerpt :Thus, SRPK2 is a potential therapeutic target for mTORC1-driven tumors [346]. Overexpression of FASN and altered metabolism in prostate cancer cells is associated with the inactivation of the tumor suppressor PTEN [91,347,348]; accordingly, PTEN expression is inversely correlated with FASN expression in prostate cancer [349], while inhibition of PTEN leads to the overexpression of FASN in vitro [92]. PTEN is a lipid phosphatase and the second most commonly mutated tumor suppressor gene in human cancers.
Lipids as Targets for Renal Cell Carcinoma Therapy
2023, International Journal of Molecular Sciences
Supported in part by National Institutes of Health SPORE grant for prostate cancer.